Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Clinical Immunology

Building Your Care Team and Preparing for Visits

At a Glance

People with APDS1 benefit from a coordinated care team led by an immunologist or complex-care clinician. Before a specialist visit, bring the PIK3CD genetic report, immune test results, pathology and imaging records, medication lists, and a timeline of infections and hospitalizations.

Managing an ultra-rare condition like APDS1 requires more than just a single doctor; it requires a coordinated “medical home.” Because APDS1 affects multiple systems—the lungs, the gut, the blood, and the immune system itself—you will likely work with a team of specialists. However, your primary immunologist or complex-care clinician should act as the “quarterback,” ensuring that all parts of the team are moving in the same direction [1][2].

Your Care Team

An effective care team for APDS1 is composed of specialists who manage the diverse manifestations of the disease. Team membership is conditional and should be based on your specific clinical findings.

  • Clinical Immunologist (The Lead): This is your most critical partner. They manage the overall immune strategy, including immunoglobulin replacement (IgRT) and targeted drugs [2][3]. They can coordinate shared care with APDS expert centers if you do not live near one.
  • Pulmonologist: Essential for monitoring lung function and managing bronchiectasis. They will review your CT scans and breathing tests to prevent long-term airway damage [4][5].
  • Hematologist/Oncologist: Many patients may need hematology input for unexplained cytopenias (low blood counts) or concerning lymphoproliferation. However, routine oncology follow-up is not necessarily required for every patient unless clinical findings dictate it [6][7].
  • Gastroenterologist: Necessary if you or your child experience chronic diarrhea, abdominal pain, or bowel inflammation (enteropathy) [8][7].
  • Other Essential Support: Depending on your needs, your team may include primary care, infectious-disease specialists, ENT, respiratory physiotherapy, nutritionists, mental-health counselors, social workers, and transplant specialists [9][10].

Vetting Your Specialist

Because APDS1 affects only 1 to 2 people per million, many excellent local doctors may never have treated a patient with this diagnosis before. A prepared specialist should be familiar with the PI3K-delta pathway and should have a clear plan for monitoring both the “underactive” and “overactive” sides of the disease [11][12].

While indicators of high-level expertise can include participation in rare disease registries, access to specialized functional lab tests, and experience with targeted therapies, the lack of immediate in-house access to these does not mean local clinicians are inadequate. A strong local immunologist can often coordinate remote consultation with a specialized inborn-errors-of-immunity center [13][14].

Preparing for Your Initial Consultation

When you meet with an APDS specialist for the first time, the “packet” of information you bring is vital. Do not rely on the doctor’s office to have transferred all your records. Having your own organized folder ensures the specialist sees the full picture.

The Visit Checklist:

  1. The Full Genetic Report: Bring the actual laboratory report for the PIK3CD gene. The specific “name” of the mutation (often listed with its HGVS notation, the standard code describing the DNA change) is critical [2][9].
  2. Functional Lab Results: If you have had functional assays—specialized laboratory tests measuring immune pathway activity—bring those results [15][16].
  3. Pathology Reports: If a lymph node, tonsil, or piece of the gut was ever biopsied, bring the full pathology report. If possible, keep track of where the actual tissue “blocks” or “slides” are stored, as a specialist may want a hematopathologist (a doctor specializing in blood and lymph node tissues) to review them again [17][6].
  4. Imaging Disc/Reports: Bring the reports—and ideally the digital files on a CD or thumb drive—for your most recent chest CT scans [18].
  5. A Chronological History: A simple one-page timeline of major events: when infections started, hospitalizations, previous surgeries, and any history of “B symptoms” (night sweats or weight loss) [11][3].
  6. Medication and Visit Essentials: Bring complete medication/allergy lists, vaccination records, infusion history, emergency plans, and insurance documents.

By providing this data upfront, you allow the specialist to spend the visit focusing on your future treatment plan rather than hunting for old data [1].

Common questions in this guide

Who usually coordinates care for someone with APDS1?
A clinical immunologist or complex-care clinician usually acts as the main coordinator for APDS1 care. This clinician helps align recommendations from specialists such as pulmonologists, hematologists, gastroenterologists, and primary care doctors, and can arrange consultation with an expert center when needed.
Which specialists might be part of an APDS1 care team?
The team depends on the person's symptoms and test results. It may include a clinical immunologist, pulmonologist, hematologist or oncologist, gastroenterologist, infectious-disease specialist, ear, nose, and throat specialist, nutrition professional, mental-health counselor, or transplant specialist.
What should I bring to a first APDS1 specialist visit?
Bring the complete PIK3CD genetic report, including the DNA-change notation, along with immune-function test results, biopsy and pathology reports, and recent chest imaging reports and digital files. A timeline of infections and hospitalizations, medication and allergy lists, vaccination and infusion records, emergency plans, and insurance information can also help the specialist plan care.
What if there is no APDS1 expert near me?
A local immunologist may be able to provide ongoing care while coordinating remote consultation with an inborn-errors-of-immunity or APDS expert center. A clinician does not need to have immediate access to every specialized test or registry to provide helpful care when communication and referral plans are in place.
How are enlarged lymph nodes evaluated in APDS1?
The immunology and hematology teams consider the person's symptoms, examination findings, imaging, and other clinical information when evaluating lymph node swelling. If a biopsy is needed, the tissue and pathology report may be reviewed by a hematopathologist who specializes in blood and lymph-node disorders.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Activated PI3K-delta syndrome 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many patients with APDS1 or similar PI3K-pathway disorders are currently under your care or in consultation with you?
  2. 2.Do you have an established pathway or a specific team of specialists (pulmonology, etc.) who work together on these cases?
  3. 3.Does this center participate in APDS registries or clinical trials, and can you help coordinate with expert centers if needed?
  4. 4.What is your process for distinguishing benign lymph node swelling from lymphoma, and which hematopathologist reviews the biopsies?
  5. 5.Who will be the single point of contact or 'quarterback' for my/my child's care to ensure that recommendations from different specialists don't conflict?

References

References (18)
  1. 1

    Diagnostic odyssey of patients with the rare immunodeficiency activated PI3 kinase delta syndrome (APDS): case study from expert and patient surveys.

    Wolf HM, Candotti F, Spelsberg R, et al.

    Frontiers in immunology 2026; (17()):1763482 doi:10.3389/fimmu.2026.1763482.

    PMID: 41859081
  2. 2

    Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives.

    IJspeert H, Dalm VASH, van Zelm MC, Edwards ESJ

    Immunotherapy advances 2024; (4(1)):ltae009 doi:10.1093/immadv/ltae009.

    PMID: 39679264
  3. 3

    Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.

    Maccari ME, Abolhassani H, Aghamohammadi A, et al.

    Frontiers in immunology 2018; (9()):543 doi:10.3389/fimmu.2018.00543.

    PMID: 29599784
  4. 4

    Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.

    Condliffe AM, Chandra A

    Frontiers in immunology 2018; (9()):338 doi:10.3389/fimmu.2018.00338.

    PMID: 29556229
  5. 5

    Infections in activated PI3K delta syndrome (APDS).

    Brodsky NN, Lucas CL

    Current opinion in immunology 2021; (72()):146-157 doi:10.1016/j.coi.2021.04.010.

    PMID: 34052541
  6. 6

    Epstein-Barr Virus-Positive B-Cell Lymphoproliferative Disorder Complicated by Septic Shock in Activated PI3Kδ Syndrome: A Pediatric Case Report and Literature Review.

    Zhao X, Ming X, Shang Z, et al.

    Case reports in hematology 2026; (2026()):3644513 doi:10.1155/crh/3644513.

    PMID: 42591980
  7. 7

    Case Report: EBV Chronic Infection and Lymphoproliferation in Four APDS Patients: The Challenge of Proper Characterization, Therapy, and Follow-Up.

    Rivalta B, Amodio D, Milito C, et al.

    Frontiers in pediatrics 2021; (9()):703853 doi:10.3389/fped.2021.703853.

    PMID: 34540765
  8. 8

    Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence.

    Bloomfield M, Klocperk A, Zachova R, et al.

    Frontiers in pediatrics 2021; (9()):697706 doi:10.3389/fped.2021.697706.

    PMID: 34350147
  9. 9

    Activated phosphoinositide 3-kinase δ syndrome caused by PIK3CD mutations: expanding the phenotype.

    Zhao P, Huang J, Fu H, et al.

    Pediatric rheumatology online journal 2024; (22(1)):24 doi:10.1186/s12969-024-00955-7.

    PMID: 38287413
  10. 10

    Case Report: Early-onset or recalcitrant cytopenias as presenting manifestations of activated PI3Kδ syndrome.

    Remiker AS, Lopes JPM, Jesudas R, et al.

    Frontiers in pediatrics 2024; (12()):1494945 doi:10.3389/fped.2024.1494945.

    PMID: 39664282
  11. 11

    Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.

    Maccari ME, Wolkewitz M, Schwab C, et al.

    The Journal of allergy and clinical immunology 2023; (152(4)):984-996.e10 doi:10.1016/j.jaci.2023.06.015.

    PMID: 37390899
  12. 12

    Report of the Italian Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome in the Target Therapy Era.

    Barzaghi F, Moratti M, Panza G, et al.

    Journal of clinical immunology 2024; (45(1)):58.

    PMID: 39714594
  13. 13

    A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.

    Rao VK, Webster S, Šedivá A, et al.

    Blood 2023; (141(9)):971-983 doi:10.1182/blood.2022018546.

    PMID: 36399712
  14. 14

    Shrinking Spleens and Nodes, Expanding Horizons: Leniolisib and the Future of Activated Phosphoinositide 3-Kinase Delta Syndrome.

    Visitsunthorn K, Rao VK

    The journal of allergy and clinical immunology. In practice 2026; (14(7)):1525-1528 doi:10.1016/j.jaip.2026.03.040.

    PMID: 42061709
  15. 15

    Technical challenges of intracellular flow cytometry-based assays as a functional complement to diagnosis of signaling defects of inborn errors of immunity: PI3K pathway as a case of study.

    Del Pino Molina L, Reche Yebra K, Soto Serrano Y, et al.

    Frontiers in immunology 2024; (15()):1476218 doi:10.3389/fimmu.2024.1476218.

    PMID: 39620215
  16. 16

    Evaluation of B-cell intracellular signaling by monitoring the PI3K-Akt axis in patients with common variable immunodeficiency and activated phosphoinositide 3-kinase delta syndrome.

    Del Pino-Molina L, Torres Canizales JM, Rodríguez-Pena R, López-Granados E

    Cytometry. Part B, Clinical cytometry 2021; (100(4)):460-466 doi:10.1002/cyto.b.21956.

    PMID: 32961022
  17. 17

    Atypical lymphoproliferations associated with germline genetic variants: a report of the 2024 EA4HP/SH lymphoma workshop.

    van den Brand M, Rásó-Barnett L, Gasljevic G, et al.

    Virchows Archiv : an international journal of pathology 2025; (487(2)):275-286 doi:10.1007/s00428-025-04189-0.

    PMID: 40748381
  18. 18

    Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension Studies.

    Diaz N, Juarez M, Cancrini C, et al.

    Journal of immunology (Baltimore, Md. : 1950) 2020; (205(11)):2979-2987 doi:10.4049/jimmunol.2000326.

    PMID: 33115853

This page is for informational purposes only and does not constitute medical advice. Your immunologist and care team should tailor referrals, testing, and visit preparation to your or your child's APDS1 needs.